Although CD20 is a hallmark cell surface molecule expressed by B cells and is the target for B cell-depleting therapy in MS, it is now recognized that some T cells express CD20, which is expressed by a higher proportion of CD8+ T cells compared to CD4+ T cells (35, 36, 42, 51). The gene discussed is CD8A; the disease is myeloid sarcoma.